Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

EPX-HTG for Structural Heart Procedures (EPX-HTG-2026)

13 de julio de 2026 actualizado por: EchoPixel, Inc.

EchoPixel Holographic Therapy Guidance (HTG) for Structural Heart Procedures

To investigate and evaluate the benefits of adding EchoPixel Holographic Therapy Guidance to the current standard of care in Structural Heart (SH) procedures.

Current structural heart (SH) procedures rely on standard image guidance (SIG) relies on 2D X-plane or multiplanar reformatted (MPR) views that can conceal critical anatomy elements at the time of implant or therapy delivery which are crucial to achieve an optimal long term durable outcome.

This limitation complicates an operator's task of optimally implanting a 3D device, delivered by tools that rotate and maneuver in 3D, within a dynamic 3D anatomy, the heart. Slight mismatches between the device and the target in the heart are indicative of a sub-optimal device position, a key risk-factor of peri-device leak (PDL) and other complications.

The primary objective of the study is to determine if including EchoPixel - HTG as an additive visualization procedural tool has a positive impact on optimal procedure outcomes for patients undergoing in Structural Heart (SH) procedures.

Descripción general del estudio

Descripción detallada

A prospective, single-center, clinical chart review.

In this trial, we will determine if the additional use of EchoPixel - HTG demonstrates a reduction in procedure time, decrease use of contrast and radiation, minimize the number of devices trialed during a procedure, determine ideal fluoroscopic viewing angles for device deployment, and optimize implant deployment and seal in in Structural Heart (SH) procedures.

The study team will compile the redacted pre- procedure CT, redacted procedural Trans-Esophageal Echo (TEE) or Intra-Cardiac Echo (ICE), procedural fluoroscopic imaging and the post device implant imaging created for each procedure case. Patient health information will be redacted and provided to physicians for review. Data will be collected on case report forms.

A prospective review will occur of outcomes regarding the Structural Heart (SH) procedure cases and data will be recorded on case report forms to compare to normal historical outcomes.

All available consecutive patients treated with the Watchman FLX device for Left Atrial Appendage Occlusion (LAAO) or MitraClip for Mitral Valve transcatheter edge to edge repair (M-TEER) will be reviewed. The primary endpoint will be to determine if EchoPixel - HTG assists in better guiding the implanter during the procedure.

All patients 18 and older scheduled for LAAO or M-TEER at the study site and whose procedure will use Philips CVx TEE or 3D ICE.

The Primary objective of the study is to determine if adding EchoPixel - HTG has a positive impact on optimal procedure success for patients undergoing an implantation of a Watchman FLX / MitraClip device compared to patients with current SIG. Procedural metrics and any procedural related complications will be recorded as secondary outcomes.

Patient demographics blinded procedural outcomes, pre-hospital discharge and complications will be monitored through and until the patient follow-up visit.

Study Execution.

Collection of data:

  1. All patients will be identified using a prospective review.
  2. The patients imaging will be de-identified and numbered with randomly picked research subject numbers identified only by site enrollment log (retained at the site only).
  3. All deidentified data imaging will be downloaded on the two separate BOX (part 11 FDA compliant) drives.

    1. CT data in one drive.
    2. TEE data in one drive.
    3. ICE data in one drive.
  4. All patient's demographics will be obtained (age, ethnicity, vitals, ejection fraction, EKG, hemoglobin, creatinine, medical history, concomitant medications, CHADS2-Vasc, HAS-BLED, primary reason for implant).

Analysis of procedural data:

  1. Procedure time in minutes.
  2. Fluoroscopic time in minutes.
  3. Radiation dose in mGy.
  4. Contrast used during the LAAO procedure in ml.
  5. Number of devices trialed during the LAAO / TEER procedure.
  6. Number of attempted device deployments / recaptures.
  7. Clinical outcomes and procedural related complications.
  8. Composite of procedure-related complications through follow-up visit.

Informed Consent Process. This is a prospective trial, utilizing redacted personal health information (PHI). Therefore, consent will be obtained.

Privacy, Confidentiality and Data Handling. The investigator will retain all regulatory documents pertaining to this study in compliance with ICH/GCP guidelines. This includes essential study documents and source documentation that support the data collected on the study Subjects. Each subject's study data will be collected and will be securely stored in the coordinating site's office. Subjects will be identified using a subject identification number. Subject information will be anonymized for data analysis.

RISKS to PARTICIPANTS. As a prospective study, all patients will be managed according to the practice's standard-of-care. As a result, there are no additional risks to the patients having their medical charts reviewed for this study. Staff and employees at the study site have extensive HIPAA training and all records will be retained at the institution. Data collection will involve the recording of protected health information; however, this PHI data will remain at the study site and only de-identified data will be shared with Echopixel. The Watchman FLX procedure / MitraClip is an FDA approved procedure.

BENEFITS to PARTICIPANTS. As an FDA approved device and procedure, there is no direct benefit to the patient. However, information gained from the study will contribute to the body of knowledge regarding the treatment of patients needing the LAAO/MitraClip procedure. Additionally, future patients who may want to consider a LAAO/MitraClip procedure will benefit from the collective published literature base of studies, such as this proposed study.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

20

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • California
      • Sacramento, California, Estados Unidos, 95187
        • University of California, Davis

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  • All patients 18 and older scheduled for LAAO or M-TEER at the study site and whose procedure will use Philips CVx TEE or 3D ICE.

Exclusion Criteria:

  • Patients whose procedures would require a GE or Siemens ultrasound system.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: EPX-HTG
Patients undergoing structural heart procedures (LAAO or M-TEER) including Holographic Therapy Guidance (HTG) as an additive visualization tool for procedure guidance.
Left Atrial Appendage Occlusion with HTG as an additive visualization tool for procedure guidance.
Otros nombres:
  • Sereno
Mitral Valve Transcatheter Edge to Edge Repair with HTG as an additive visualization tool for procedure guidance.
Otros nombres:
  • MitraClip
  • M-TEER

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Optimal Device Position.
Periodo de tiempo: 45 days post procedure.
For both LAAO and M-TEER procedures an optimal device position will be established in pre-procedure planning. The optimal device position will be evaluated at the time of the procedure and in post-procedure imaging.
45 days post procedure.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Procedure Time.
Periodo de tiempo: Perioperative/Periprocedural measurement of procedure length/duration.
Duration of procedure to implant LAAO or TEER device, in minutes.
Perioperative/Periprocedural measurement of procedure length/duration.
Fluoroscopic Time.
Periodo de tiempo: Perioperative/Periprocedural measurement of length/duration of fluoroscopy use.
Duration/length of use of fluoroscopy to implant LAAO or TEER device, in minutes.
Perioperative/Periprocedural measurement of length/duration of fluoroscopy use.
Radiation Dose.
Periodo de tiempo: Perioperative/Periprocedural measurement of total radiation dose for completing procedure/surgery.
Amount of radiation used to implant LAAO or TEER device in mGy.
Perioperative/Periprocedural measurement of total radiation dose for completing procedure/surgery.
Contrast Used.
Periodo de tiempo: Perioperative/Periprocedural measurement of total radio-opaque contrast used for completing procedure/surgery.
Amount of radio-opaque contrast used to implant LAAO or TEER device, in ml.
Perioperative/Periprocedural measurement of total radio-opaque contrast used for completing procedure/surgery.
Number of devices trialed for procedure completion.
Periodo de tiempo: Perioperative/Periprocedural count of the total number of devices (LAAO or TEER) utilized/required to complete the procedure/surgery.
The total number of devices (LAAO or TEER) utilized/required to complete the procedure.
Perioperative/Periprocedural count of the total number of devices (LAAO or TEER) utilized/required to complete the procedure/surgery.
Number of Device Deployments.
Periodo de tiempo: Perioperative/Periprocedural count of the total number of times a device is positioned for final deployment in order to be released from the delivery catheter in order to complete the procedure/surgery/
The total number of times a device is positioned for final deployment in order to be released from the delivery catheter.
Perioperative/Periprocedural count of the total number of times a device is positioned for final deployment in order to be released from the delivery catheter in order to complete the procedure/surgery/
Procedure-related complications.
Periodo de tiempo: Perioperative/Periprocedural and throughout 45-day follow-up visit.
Composite of any procedure-related complications for LAAO or M-TEER.
Perioperative/Periprocedural and throughout 45-day follow-up visit.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Gagan D Singh, MD, UC Davis Health

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

3 de agosto de 2026

Finalización primaria (Estimado)

31 de diciembre de 2026

Finalización del estudio (Estimado)

30 de octubre de 2027

Fechas de registro del estudio

Enviado por primera vez

30 de junio de 2026

Primero enviado que cumplió con los criterios de control de calidad

13 de julio de 2026

Publicado por primera vez (Actual)

15 de julio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

15 de julio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

13 de julio de 2026

Última verificación

1 de julio de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir